Name | LP-184 |
---|
Description | LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2). |
---|---|
Related Catalog | |
Target |
IC50: 0.68 μM (HT29); 0.6 μM (OVCAR-3); 16 μM (AsPC-1); 0.14 μM (PC-3) |
In Vitro | LP-184 inhibits the growth of HT29, OVCAR-3, AsPC-1 and PC-3, with GI50s of 0.68, 0.6, 16 and 0.14 μM, respectively[1]. LP-184 displays IC50s of 800nM and 210 nM for anti-cancer activitie in the thymidine incorporation into cellular DNA (2 hour) and Trypan blue (48 hour) assay[1]. |
In Vivo | LP-184 (7.5 and 10 mg/kg; i.p.; 21 day) has potent 15 anti-tumor activity against MV522 tumors, producing 4/6 and 5/5 partial responses, respectively[1]. Animal Model: Mice (MV522 tumors) [1] Dosage: 7.5 and 10 mg/kg Administration: I.p; 21day Result: Effective agent for human anti-tumor therapy. |
References |
[1]. Trevor C. Mcmorris, et al. Illudin analogs useful as anticancer agents. WO2007019308A2. |
Molecular Formula | C16H20N2O4 |
---|---|
Molecular Weight | 304.34 |